

Index

a

A β brain clearance 342–343
 aberrant protein glycosylation
 161–163
 A β o, inhibitors of 338–341
 A β protein precursor (APP) 293
 acceptor protein 32
 acetalated dextran (Ac-Dex) 89
 acetophloroglucinol 333, 336, 338
 acetylcholine (ACh) 294, 295, 324,
 325, 329, 330
 acetylcholinesterase (AChE) 294, 324,
 325, 327–329
 acetylcholinesterase inhibitors
 294, 329
 active site-specific chaperone
 (ASSC) 252
 adaptative immune responses 87
 adhesin receptors 132
 adjuvant 89
 AGA*IA 355, 362
 amide coupling 78
 amyloid β oligomers (A β o) 294, 330
 β -amyloid precursor protein
 (APP) 293, 295, 297
 amyloid protein–protein
 interaction 334–338
 antiadhesion therapy 132

antibody-dependent cell-mediated
 cytotoxicity (ADCC) 202,
 203, 209–212
 antibody immunogenicity 204
 anti-GD2 antibodies 210, 212, 213
 antigen-presenting cells (APCs) 14,
 15, 24, 25, 87, 88, 94, 96
 anti-influenza inhibitors 89–90
 antimicrobial resistance (AMR) 2, 132
 antithrombin mediated
 activity 357–360
 antithrombotic drugs 354
 APP intracellular domain (AICD) 297
Aspergillus fumigatus 66–68
 AT binding pentasaccharide sequence
 (ATBPS) 355
 atomic force microscopy
 (AFM) 61, 335
 autocatalytic reaction 294
 average degree of polymerization
 (avDP) 17, 26, 31

b

bacterial adhesins 132, 143–148
 bacterial artificial chromosomes
 (BACs) 205
 bacterial glycolipid lipid A 113–117
 bacterial lectins 131, 132

- benzoylation reaction 332
- bicyclononyne (BCN) 30
- bioengineered glycoconjugates 31–33
- bispecific antibodies 213
- blood brain barrier (BBB) 248–250, 252, 255, 263, 272, 312, 337
- blood group 206–207
- bnAb epitope mimics 75, 78, 81–84
- bone metabolism 361
- bovine serum albumin (BSA) 63, 65, 78, 79
- brain dysmetabolism 299
- broadly neutralizing antibodies (bnAbs) 74–77, 81–83, 85, 86, 91
- bump-and-hole strategy 174
- 1,4-butanediol diglycidyl ether (BDDE) 226
- butyrylcholinesterase (BChE) 325, 327–330
- butyrylcholinesterase inhibitors 294, 328, 329
- C**
- Candida albicans* 61–64
- Candida auris* 61–64
- capillary electrophoresis (CE) 178
- carbohydrate antigens 15–18, 24, 26, 29, 33, 75, 87, 164, 165
 - in fungal cell wall 60–61
- carbohydrate antiviral agents 92–93
- carbohydrate-based adjuvant candidates 95–96
- carbohydrate-based vaccines 5–15
- carbohydrate derivatives 139–141
- carbohydrate epitopes 91, 131–134, 137, 141, 153
- carbohydrate-protein conjugation 19–21
- carbohydrate-protein interactions 38, 131–132, 295, 341–343
- carbohydrate recognition domains (CRDs) 132, 138
- carbohydrates 73
- carcinoembryonic antigen (CEA) 168
- carrier-induced epitope suppression 22, 23, 26
- carrier protein 15, 16, 19, 22–24, 26, 32, 36, 37, 78, 83
- catheter-associated urinary tract infections (CAUTI) 133
- cell apoptosis 293
- cellular prion protein (PrP^C) 294, 330, 331, 334
- chemoenzymatic approach 30–31, 38
- chemoenzymatic synthesis 28, 30, 31, 82, 169, 369
- chimeric antigen receptors (CARs) 213–214
- chitin deacetylation 324
- chitosan (CTS) and derivatives in AD brain 324–325
- cholera vaccines 117
- cholinesterase inhibitors 325–330
- chondroitin sulfate (CS) 225, 227, 254, 363
- chondroitin sulfate proteoglycans (CSPGs) 295, 323
- Claisen–Schmidt aldol condensation 336
- click chemistry 21, 88, 92, 93, 174, 175, 236, 267
- collision-induced dissociation (CID) 181
- combined ERT/PC therapy 254, 260, 275
- complementarity determining region (CDR) grafting 204
- complement-dependent cytotoxicity (CDC) effect 202
- covalent linkage free macromolecular complexes 36
- COVID-19 vaccines 95–96

- CRISPR/Cas9 system 173
 cross reacting material 197
 (CRM₁₉₇) 17, 22, 23, 32
Cryptococcus neoformans 60, 64–66
 C-type lectin receptors
 (CLRs) 133, 135
 CuAAC cycloaddition 83
 cutaneous lesions 226
 cutting-edge strategy 28
 cytotoxic T lymphocyte (CTL) 208
- d**
- dalteparin 361, 362
 danaparoid 363, 365
 DC-SIGN ligands 137
 carbohydrate derivatives or
 glycomimetics 139–143
 natural carbohydrate
 epitopes 136–138
 DC-SIGN targeting 136
 deep vein thrombosis (DVT) 353, 354,
 361, 365, 366
 defibrotide (DF) 354, 366
 dendrimers 137
 1-deoxygalactonojirimycin (DGJ) 268
 1-deoxynojirimycin (DNJ) 266, 275
 depolymerization method 362
 dermatan sulfate 254, 353, 356, 364
 diphtheria toxin (DT) 17, 22
 direct gene transfer 248
 direct protein–protein interaction 359
 disability-adjusted life year
 (DALY) 1, 2
 divinyl sulphone (DVS) 226
 Dixon plot analysis 316
 dynamic light scattering 61
- e**
- ebola virus (EBOV) 91–93
 electron transfer dissociation
 (ETD) 181
 emulsion techniques 89
 endotoxins 111, 113
 enoxaparin 361, 362
 envelope glycoprotein (Env) 74, 92, 96
 enzymatic formation 30–31
 enzymatic transglycosylation 83
 enzyme replacement therapy
 (ERT) 248, 250–251
 EP217609, 368
 ER-associated degradation (ERAD)
 pathway 252
 extracellular matrix (ECM) 161, 211,
 223, 355, 364
- f**
- Fab fragments 202–204
 Fabry disease (FD) 250, 258–262
 fanolesomab 207
 FAS ligand (FASL) 208
 fast-moving heparin (Fm-Hep)
 fraction 364
 fermented foods 118–120
 focal adhesion kinase (FAK) 211
 Fondaparinux 354, 362, 363, 367–369
 formalin-fixed paraffin-embedded
 (FFPE) 165, 166
 formamidine acetate 331, 332
 Friedel–Crafts type mechanism 332
 fungal cell wall 60–61
 fungal pathogens, immunity
 against 59
 fXa inactivation 359
 Fyn kinase inhibitors 295,
 330–334, 337
- g**
- GAG mixtures 354, 363–366
 β-galactocerebrosidase
 (GALC) 275, 276
 β-galactocerebroside (GalCer) 275
 galactosamine (GalN) 66
 galactosaminogalactan (GAG) 66
 structures 67

- galactose (Gal) 66
- galactoxylomannan (GalXM) 64
- α -Gal-based vaccine constructs 87–88
- α -Gal epitope 88, 94
- GalNAc, in
 - neurodegeneration 322–323
- 2G12 antibody 75–76
- Gatipotuzumab 207
- Gaucher disease (GD) 262–267
- GBS polysaccharide-based conjugate vaccine 21
- generalized modules for membrane antigens (GMMA) 33–34
- genetic glycoengineering 173
- 2G12 epitope mimics 76–81
- GlcNAcstatins 295, 299, 305–311, 316
- globoid cell leukodystrophy 275
- Globo Series 206–207
- globotriaosylceramide (Gb3) 258
- glucocerebrosidase (GCase) 253, 262
- glucose metabolism 297
- glucosylceramide synthase (GCS) 258, 262, 272
- glucuronoxyloymannan (GXM) 64
- glycan arrays 82, 206
- glycan-binding proteins (GBPs) 162
- glycan microarrays 169, 171, 174, 183
- glycan–protein coupling 17, 23
- glycocalyx 5, 161
- glycoconjugates
 - nonprotein-based 36
 - structural elucidation of 176–182
- glycoconjugate vaccines 7, 10
 - adjuvants 24–25
 - against *Aspergillus fumigatus* 66–68
 - against *Candida albicans/Candida auris* 61–64
 - carbohydrate antigen 16, 18
 - carbohydrate-protein conjugation 19, 21
 - carrier protein 22, 24
 - components of 15–16
 - against *Cryptococcus neoformans* 64–66
 - development of 6, 14, 15, 22, 25, 60
 - nanotechnology-based strategies 33
 - production of 25–26
 - synthetic carbohydrate antigens 28–29
 - traditional 26, 28
- glycoengineered *ex vivo* models 171–176
- glycoengineered *in vitro* models 171–176
- glycoengineered *in vivo* models 171–176
- glycoengineered outer membrane vesicles (geOMVs) 34
- glycoepitopes 16, 22, 28
- glycogen storage disorders 246, 253, 275–279
- glycolipid disialoganglioside (GD2) 201, 209
- glycomic strategies 176–182
- glycomimetics 131–153, 266, 294
- glycoprotein-based vaccines 92
- glycoproteinoses 253, 277–279
 - alpha-mannosidosis 279–280
 - fucosidosis 277, 279
- glycoproteins 132
- glycoproteomic strategies 176–182
- glycosaminoglycans (GAGs) 132, 169, 224–225, 254, 294, 323
- glycosidase inhibitors 301
- glycosignature, on cell surfaces 223
- glycosphingolipids 132, 148, 161, 249, 251, 272, 341
- glycosyltransferases (GTs) 32, 171, 369
- GM2 activator protein (GM2-AP) 272
- GM1 gangliosidosis 268–272, 282
- GM2 gangliosidosis 272–275
- gold glyconanoparticles (AuGNPs) 255

- gold nanoparticles (GNPs) 34–35, 137–138
- Gram-negative bacteria 4, 33, 111, 113, 117–119, 123
- Gram-positive bacteria 33
- granulocyte–macrophage colony stimulating factor (GM-CSF) 205, 209, 210, 212, 213
- GT-coding gene 172, 173
- gut-associated lymphoid tissues (GALT) 123
- h**
- haematopoietic stem cell transplantation (HSCT) 248, 255, 272, 279
- haematoxylin and eosin (HE) staining 324
- hemagglutinin (HA) 86–88
- heparan sulphate proteoglycans (HSPGs) 227
- heparin
adverse effects of 360–361
coating 229
- heparin cofactor II mediated activity 360
- heparin-induced thrombocytopenia (HIT) 361
- hepatitis C virus (HCV) 90–91
- hepatocellular carcinoma (HCC) 90, 166
- Hexa-AfLA 125
- β -hexosaminidase 272–275, 302, 311, 316
- higher energy collisional dissociation (HCD) 181
- high-performance liquid chromatography (HPLC) 178
- high-throughput screening (HTS) 249
- homobifunctional linkers 19, 20
- Horner–Wadsworth–Emmons olefination 340
- human anti-mouse antibodies (HAMA) 204, 211, 212
- human fungal infections 57–59
- human immunodeficiency virus type 1 (HIV-1) 74–75
- human O-GlcNAcase (hOGA) 299–302, 306, 308, 311, 312, 315–317, 320
- Hyalograft C 226
- hyaluronic acid benzyl ester 226
- hydrazide chemistry 180
- hyperglycosylated HA vaccines 87
- i**
- IdoA conformation 356
- Idrabiotaparinux 368
- Idraparinux 368
- IgG antibodies 202
- IgM antibodies 203
- imaging mass spectrometry (IMS) 164–166
- immunogenic carrier protein 18
- immunoprophylaxis 58
- immunostimulatory effect 96, 111, 113, 118, 119, 121, 122
- implantable medical devices 234–235
- indirect gene transfer 248
- influenza A viruses (IAVs) 85–90
- in situ* proximity ligation assay 166–168
- interferon (IFN) regulator 3 (IRF3) 113
- interleukin 2 (IL-2) 209, 210, 212
- interleukin-6 (IL-6) 324
- intracerebroventricular-streptozotocin (ICV-STZ) 324
- invasive fungal infections (IFIs) 57
- in vitro* opsonophagocytic assay 63
- k**
- keyhole limpet hemocyanin (KLH) 62, 76
- knock-ins (KIs) 173

knock-out (KO) 172, 173
knock-out mutation 205
KO/KI strategies 174
Krabbe disease (KD) 275–276

l

leukodystrophies 275
linear polymers 138, 139, 324
lipid A-based self-adjuvating
vaccines 125–126
lipid-raft gangliosides 341–342
lipid rafts 342
lipoarabinomannan (LAM) 36
lipooligosaccharides (LOS) 78, 123
lipopolysaccharide (LPS) 4, 5
and lipid A 111, 118–120
liposomal encapsulation of
polysaccharides (LEPS) 35
liposomes 34–35, 80, 125
long-term thromboresistance 228
low-and middle-income countries
(LMIC) 1
low-molecular weight dextran sulfate
(LMW-DS) 231
low molecular weight heparins
(LMWHs) 353, 354, 359,
361–363, 368
lysosomal storage disorders
(LSDs) 245–246
combined ERT/PC therapy 254
enzyme replacement therapy
(ERT) 250–251
glycogen storage disorders 275–278
glycoproteinoses 277–279
mucopolysaccharidoses
(MPS) 254–257
pharmacological chaperone therapy
(PCT) 252–253
role of carbohydrate-based
therapeutics 248–254
sphingolipidoses 258–276

substrate reduction therapy
(SRT) 251–252

m

major histocompatibility complex class
II (MHC-II) 14, 15
mannoproteins (MP) 64
 α -mannosidosis 279, 280, 282
matrix-assisted laser desorption/
ionization (MALDI)-IMS 165
membrane blebbing process 33
mesoglycan 363, 365–366
metabolic glycoengineering
(MGE) 235–236
methoxymethyl ether (MOM) 336
Michaelis–Menten kinetics 314
Mitsunobu coupling 332
monoclonal antibodies (mAbs) 58,
92–93, 162, 204
binding, to neuroblastoma
211–212
monophosphoryl lipid A (MPLA) 24,
25, 36, 95, 112
Morquio B disease (MBD)
268–272
mucin attached glycans 206, 207
mucopolysaccharidoses (MPS)
254–257
multivalent constructs 89–90
murine 3F8, 211, 212
murine IgG3 (m3F8) 211
murine IgG2a (14G2a) 211

n

nadroparin 361, 362
nanomolar inhibition 327
natural killer cells (NK) 210
natural LPS 117–118
natural polysaccharides 224
Naxitamab 205, 208, 212–214
N-butyl-DNJ 251, 252
neuraminidase (NA) 86, 88–89

- neuroblastoma
 GD2 antibody-targeted
 destruction of 210
 mAbs binding to 211–212
- neurofibrillary tangles
 (NFTs) 293, 296–299
- neuroinflammation 272, 275, 324, 343
- NeuroSpec™ 207
- N-hydroxysuccinimidyl (NHS)
 esters 19
- Niemann–Pick (NP)
 disorders 267–268
- N-linked glycan masking 87
- N-linked glycosylation system 31
- N-methyl-D-aspartate receptor
 (NMDA) 331
- nojirimycin (NJ) analogs 263
- nonprotein-based glycoconjugates 36
- nuclear magnetic resonance
 (NMR) 61, 64, 336
- nuclease-based genome editing 173
- O**
- O-antigen polysaccharide 116, 117
- OGA inhibitors 298–301, 317, 322
- O-GlcNAc cycling 295–299
- O-GlcNAc hydrolase (OGA) 295–322
- O-GlcNAc transferase (OGT) 295–322
- O-GlcNAcylation 293, 295–299,
 308, 322
- oligosaccharides (OSs) 15, 17
- open reading frame (ORF) 173
- ophthalmic viscoelastic devices
 (OVDs) 226
- osteoarthritic (OA) knee 227
- osteoporosis 361
- outer membrane protein complex
 (OMPC) 22, 77
- outer membrane vesicles
 (OMVs) 33–34
- oxazolinium ion 299
- oxidative stress-induced
 neurotoxicity 338–341
- P**
- Pan-Assay Interference compound
 (PAIN) 334, 339
- pan-fungal vaccine 68
- parasitic bacterial lipid A 121–123
- pathogen-associated molecular patterns
 (PAMPs) 14, 59, 61
- pathogen recognition receptor
 (PRR) 60
- pathogen recognition receptors
 (PRRs) 14, 92
- patient-derived xenografts (PDX) 176
- pattern recognition receptors
 (PPRs) 59, 133
- pentosan polysulfate (PPS) 354, 367
- peptide-*N*-glycosidase F
 (PNGase F) 165
- pharmacodynamic effects 321
- pharmacological chaperone
 (PC) 249, 256
- pharmacological chaperone therapy
 (PCT) 249, 252–253
- piperidine iminosugars 259, 282
- platelet factor 4 (PF4) 361
- polysaccharide antigens 60, 68
- polysaccharide-based vaccines 4–5
- polysaccharides
 from algae 228, 230–233
 from animal and microbial
 fermentation 228, 230–233
 from plants 228, 230–233
- Pompe disease (PD) 246, 275, 277,
 278, 282
- porous graphitized carbon (PGC) 178
- positive ion mode analysis 177, 179
- Positron Emission Tomography
 (PET) 297
- protein-based vaccines 4

- protein-carbohydrate
 - interactions 168, 170, 344
 - protein C inhibitor (PCI) 360
 - protein D (PD) 22, 23
 - Protein Glycan Coupling Technology (PGCT) 31
 - protein glycosylation 18, 29, 32, 163, 171
 - protein-polysaccharide conjugate 15
 - proteoglycans (PGs) 5, 161, 224–225, 323
 - PUGNAc 295, 299, 301–305, 311
 - pulmonary embolism (PE) 353, 354
 - pyrrolidine iminosugars 259, 263
- R**
- RBD-based constructs 95
 - recurrent vulvovaginal candidiasis (RVVC) 58
 - regenerative medicine 233–234
 - glycoengineering application to 235–236
 - regioselective conjugation
 - techniques 29
 - replication-defective canarypox
 - vector 74
 - reverse vaccinology 4
 - RON receptor tyrosine kinase (RTK) 168
- S**
- Salmonella enterica* serovar Typhi
 - vaccines 117
 - saponins 95–96
 - saracatinib 331, 332
 - Saturation Transfer Difference (STD)
 - NMR screening assays 336
 - Scatchard analysis 210
 - self-adjuvanting approach 25
 - severe acute respiratory syndrome
 - coronavirus-2 (SARS-CoV-2) virus 94–96, 133
 - Siglecs 171, 174, 343
 - single chain fragment variable (scFv) 203–204
 - site-selective conjugation 21, 29, 32
 - site-selective protein
 - conjugation 29–30
 - slow-moving heparin
 - (Sm-hep) 365–366
 - Sphingolipidoses
 - Fabry disease 258–262, 292
 - Gaucher disease 262–267
 - GM2 gangliosidosis 272–275
 - GM1 gangliosidosis and Morquio B (β -Gal) 268–272
 - Krabbe disease (KD) 275–276
 - Niemann-Pick (NP)
 - disorders 267–268
 - static light scattering 61
 - strain-promoted azide alkyne
 - cycloaddition (SPAAC) 23
 - streptozotocin (STZ) 299
 - substrate reduction therapy
 - (SRT) 248, 251–252
 - subunit vaccines 4–5, 73, 96, 117, 118
 - sulfated polysaccharides 224, 227, 231
 - sulodexide 363–365
 - surface oligomannose cluster targeting
 - bnAb 75–76
 - surface plasmon resonance (SPR) 76, 139, 170
 - Swern oxidation 306, 308, 326
 - symbiotic bacterial lipid
 - A 121, 123–125
 - synthetic and semisynthetic lipid 120
 - synthetic carbohydrate
 - antigens 28–30
 - synthetic glycoconjugates 80, 83
 - synthetic Man₄, 77
 - synthetic oligosaccharides 61, 65, 67, 367–368

t

Tau aggregation 322
 Tau protein 293, 330
 T carb cells 15
 T cell-dependent (TD) antigens 14
 T cell receptor (TCR) 14, 15, 34
 tetanus toxoid (TT) 17, 22
 T helper antigen 22, 35
 T helper protein/peptide antigen 22
 Thiamet-G 299, 311–313,
 315–317, 321
 thiazoline inhibitors 299, 311–322
 tinzaparin 361, 362
 tissue engineering
 medical devices
 formulation 224–233
 natural and synthetic
 strategies 224–234
 and regenerative medicine 233–234
 tissue factor pathway inhibitor
 (TFPI) 360, 365, 368
 tissue microarray (TMA) 165
 TLR4/MD-2 dimerization 114–116
 TLR4 signaling regulation 113
 Toll gene 113
 Toll/IL-1R (TIR) domain 113
 Toll-like receptor-4 (TLR4) 24
 Toll-like receptors (TLR) 24, 111
 toxoid vaccines 4
 traditional glycoconjugates 26–28
 trans-cyclooctene (TCO) 30
 transgenic animals 204–205
 trifluoroacetic acid (TFA) 302, 308,
 313, 314, 322
 triphenylphosphane
 hydrobromide 339
 tumor-associated carbohydrate antigens
 (TACAs) 162, 201
 tumor necrosis factor- α (TNF- α) 324
 tyrosine gate 145, 147

u

ultra low molecular weight heparins
 (ULMWHs) 363
 undecaprenyl pyrophosphate
 (Und-PP) 32
 Unituxin 205, 206, 208–211,
 213, 214
 urinary tract infections (UTIs) 133

v

vaccines
 carbohydrate-based 5–15
 cholera 117
 COVID-19 95–96
 development 95
 GBS polysaccharide-based
 conjugate 21
 glycoconjugate 7, 10
 glycoprotein-based 92
 history of 2, 5
 hyperglycosylated HA 87
 lipid A-based
 self-adjuvating 125–126
 non-covalent 36–37
 pan-fungal 68
 polysaccharide-based 4–5
 protein-based 4
 subunit 4–5, 73, 96, 117, 118
 toxoid 4
 whole-cell attenuated 4
 whole-cell killed/inactivated 4
 variolae vaccinae 3
 V3-directed bnAb epitope mimics
 83
 venous thromboembolism (VTE)
 354
 virtual conjugate 37
 virus-like particles 34–35, 79
 V3-targeting bnAbs 83
 V1V2-targeting bnAbs 81

W

whole-cell attenuated vaccines 4

whole-cell killed or inactivated
vaccines 4

X

xenoantigens 224, 234, 235

X-ray crystallography 113, 114

Y

years lived with disability (YLD) 1

years of life lost to premature
death (YLL) 1

yeast artificial chromosomes (YACs) 205

Z

zwitterionic polysaccharide (ZPS) 206

